- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Ipsos Healthcare Launches Syndicated MS Patient Community Panel
Ipsos Healthcare has announced the launch of its syndicated Multiple Sclerosis (MS) Patient Community Panel, part of the Ipsos Healthcare Global Patient Centre of Excellence. The MS Patient Community Panel comprises MS patients across the EU5 and US with a mix of treatment experiences. They will take part in a range of tasks throughout the year (both syndicated and proprietary), moderated by Ipsos Healthcare’s MS experts. This format will enable subscribers to explore key topics throughout the year, whilst also tapping into the community to answer business questions as they arise. Paul O’Meara, Head of Real World Evidence in Autoimmune Diseases at Ipsos Healthcare, commented: “As patients move from recipients to participants, there is an imperative for pharma to put patients at the heart of current and future business models. Designed with this objective in mind, the MS Community will enable our clients to identify unmet patient needs, optimise their patient communications, assess new ideas, and develop personalized medicine strategies for those living with MS.”
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
